End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
58.42 CNY | +1.62% |
|
+3.36% | -12.71% |
06-26 | Sunflower Pharmaceutical Group Co.,Ltd Announces Board Appointments | CI |
04-29 | Bloomage BioTechnology Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 50% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The company is in a robust financial situation considering its net cash and margin position.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.38 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.91 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.71% | 3.85B | C | ||
+4.57% | 96.72B | A- | ||
+5.66% | 41.43B | A- | ||
-13.20% | 32.7B | B- | ||
+79.15% | 29.06B | A | ||
-16.02% | 15.38B | C | ||
-8.17% | 12.97B | B- | ||
-13.35% | 11.36B | D+ | ||
+160.91% | 9.9B | D | ||
-56.29% | 8.79B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 688363 Stock
- Ratings Bloomage BioTechnology Corporation Limited